Degenerative Disease News and Research

RSS

Eating brightly colored fruit and veg may help prevent ALS

Having a high intake of carotenoids, compounds that give certain fruits and vegetables their distinctive coloring, can reduce a person’s risk for developing amyotrophic lateral sclerosis or motor neurone disease, suggest study findings.

4 Feb 2013

Androgens could constitute an efficient treatment against multiple sclerosis

Testosterone and its derivatives could constitute an efficient treatment against myelin diseases such as multiple sclerosis, reveals a study by researchers from the Laboratoire d'Imagerie et de Neurosciences Cognitives, in collaboration in particular with the "Neuroprotection et Neurorégénération: Molécules Neuroactives de Petite Taille" unit.

30 Jan 2013

Consuming carotenoid-rich foods may help prevent or delay onset of amyotrophic lateral sclerosis

New research suggests that increased consumption of foods containing colorful carotenoids, particularly beta-carotene and lutein, may prevent or delay the onset of amyotrophic lateral sclerosis (ALS).

29 Jan 2013

Leprosy bacteria able to change the make-up of Schwann cells

A discovery about the way in which bugs spread throughout the body could help to develop stem cell treatments.

19 Jan 2013

Apparent stem cell transplant success in mice may hold promise for people with ALS

Apparent stem cell transplant success in mice may hold promise for people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.

11 Jan 2013

Non-surgical orthopedic medical devices: an interview with Brian Moore, Director of Sales and Product Marketing from DJO global

Non-surgical orthopedic medical devices are products designed to help relieve pain in specific parts of the body.

10 Oct 2012

FDA panel recommends U.S. approval for Second Sight’s Argus II bionic eye

On Friday September 28th, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, an important step toward the FDA market approval of this product manufactured by Second Sight Medical Products, Inc.

3 Oct 2012

Zinc deficiency mechanism associated with many health problems, aging

A new study has outlined for the first time a biological mechanism by which zinc deficiency can develop with age, leading to a decline of the immune system and increased inflammation associated with many health problems, including cancer, heart disease, autoimmune disease and diabetes.

2 Oct 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Researchers isolate elusive human gene that causes NMNAT1-related Leber congenital amaurosis

Researchers from the Massachusetts Eye and Ear Infirmary, The Children's Hospital of Philadelphia, Loyola University Chicago Health Sciences Division and their collaborators have isolated an elusive human gene that causes a common form of Leber congenital amaurosis (LCA), a relatively rare but devastating form of early-onset blindness. The new LCA gene is called NMNAT1.

30 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Second Sight Medical Products Inc., the world's leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review the data presented in the company's Humanitarian Device Exemption (HDE) market approval application for its Argus II Retinal Prosthesis System (Argus II prosthesis) on September 28, 2012 in Gaithersburg, Maryland.

21 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Study into how IDPN nitrile causes neurological syndromes similar to ALS

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) at the University of Barcelona (UB) have coordinated a research into how the IDPN nitrile causes neurological syndromes similar to those of the amyotrophic lateral sclerosis (ALS), a severe neuromuscular degenerative disease.

18 Jul 2012

New class of injectable materials can stimulate tissue regeneration

The University of Nottingham has begun the search for a new class of injectable materials that will stimulate stem cells to regenerate damaged tissue in degenerative and age related disorders of the bone, muscle and heart.

6 Jul 2012

DHA and curcumin help maintain neurological function after degenerative damage

UCLA researchers discovered that a diet enriched with a popular omega-3 fatty acid and an ingredient in curry spice preserved walking ability in rats with spinal-cord injury. Published June 26 in the Journal of Neurosurgery: Spine, the findings suggest that these dietary supplements help repair nerve cells and maintain neurological function after degenerative damage to the neck.

27 Jun 2012

DHA and curcumin preserve walking ability in rats with spinal-cord injury

UCLA researchers discovered that a diet enriched with a popular omega-3 fatty acid and an ingredient of curry spice preserved walking ability in rats with spinal-cord injury. Published June 26 in the Journal of Neurosurgery: Spine, the findings suggest that these dietary supplements help repair nerve cells and maintain neurological function after degenerative damage to the neck.

27 Jun 2012

New system may help restore vision in eye diseases

Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases.

14 May 2012

Study reveals evidence about harmful effects of glycogen accumulation in neurons

Collaborative research by groups headed by scientists Joan J. Guinovart and Marco Mil-n at the Institute for Research in Biomedicine (IRB Barcelona) has revealed conclusive evidence about the harmful effects of the accumulation of glucose chains (glycogen) in fly and mouse neurons.

3 May 2012